The Supreme Court declined to review a petition filed by Novartis’ Sandoz unit that challenged two of Amgen’s patents on its blockbuster rheumatoid arthritis drug, Enbrel, meaning there won’t be a ...

ZURICH (Reuters) - The U.S. Food and Drug Administration has accepted Novartis unit Sandoz's regulatory submission for approval of a biosimilar copy of Amgen's blockbuster Enbrel drug, the Swiss ...

For instance, the FDA licensed Sandoz’s biosimilar for Enbrel, a popular drug to treat autoimmune disorders, in 2016, but Sandoz won’t be able to market its competitor in the U.S. until 2029 at the ...

Erelzi was developed by Sandoz — a division of Switzerland-based Novartis — and is intended to treat a variety of inflammation conditions, including rheumatoid arthritis and plaque psoriasis. The FDA ...

Alston & Bird allege their client has suffered more than $1 billion in lost sales from being unable to manufacture a biosimilar product in the United States to compete with Amgen's blockbuster Enbrel ...

Alston & Bird represent plaintiff Sandoz Inc. in an antitrust lawsuit against Amgen. Munger, Tolles & Olson and Kaufman & Canoles represent Amgen in a related case in the Eastern District of Virginia.

Sandoz Group AG (OTC:SDZNY) (OTC:SDZXF) on Monday filed an antitrust lawsuit in the U.S. against Amgen, Inc. (NASDAQ:AMGN) for extending and entrenching the dominant market position of its blockbuster ...

Sandoz has filed an antitrust lawsuit in the United States against Amgen, for extending and entrenching the dominant market position of its blockbuster medicine, Enbrel (etanercept). The drug was ...

While the FDA is streamlining regulation of copycat versions of the expensive drugs that millions take for arthritis, cancer, and other diseases, the U.S. patent office is making it harder for the ...

While the FDA is streamlining regulation of copycat versions of the expensive drugs that millions take for arthritis, cancer, and other diseases, the U.S. patent office is making it harder for the ...